ReviewJournal of clinical immunology2010
Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.
Review in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.European journal of neurology · 2021Trial
- Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.Journal of clinical immunology · 2011Trial
- Clinical and experimental treatment of primary humoral immunodeficiencies.Clinical and experimental immunology · 2024Review
- An updated review on activated PI3 kinase delta syndrome (APDS).Genes & diseases · 2020Review
- Fatigue and the wear-off effect in adult patients with common variable immunodeficiency.Clinical and experimental immunology · 2018Article
- The Treatment of Activated PI3Kδ Syndrome.Frontiers in immunology · 2018Review
- Dosing and individualized treatment - patient-centric treatment: changing practice guidelines.Clinical and experimental immunology · 2014Article
- Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies.Journal of clinical immunology · 2014Article
- Clinical use of polyvalent immunoglobulins.Blood transfusion = Trasfusione del sangue · 2013Review
- Polyvalent immunoglobulins: challenges and perspectives.Blood transfusion = Trasfusione del sangue · 2013Review
- Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.Clinical medicine (London, England) · 2013Article
- Bioavailability of IgG administered by the subcutaneous route.Journal of clinical immunology · 2013Article
- Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.Clinical and experimental immunology · 2011Review
- New Frontiers in Subcutaneous Immunoglobulin Treatment.Biologics in therapy · 2011Review
- International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.The journal of allergy and clinical immunology. In practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Oxford Programme for Immunomodulatory Immunoglobulin Therapy has been operating since 1992 at Oxford Radcliffe Hospitals in the UK. Initially, this program was set up for patients with multifocal motor neuropathy or chronic inflammatory demyelinating poly-neuropathy to receive reduced doses of intravenous immunoglobulin (IVIG) in clinic on a regular basis (usually every 3 weeks). The program then rapidly expanded to include self-infusion at home, which monitoring showed to be safe and effective. It has been since extended to the treatment of other autoimmune diseases in which IVIG has been shown to be efficacious.
methodsThis review includes details of the program such as the training of patients, dosing with immunoglobulin, and monitoring and compliance for self-infusion at home, with cases to illustrate these points.
resultsIn addition, the Evidence for efficacy and the effects of confounding morbidities will be are included described. More recently, subcutaneous immunoglobulin therapy (SCIG) has been used in several chronic autoimmune peripheral neuropathies and in epidermolysis bullosa acquisita, with equally good effect. Trials of SCIG in other autoimmune diseases are planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.